Drug Trial Radar · NCT04165070
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
Last checked: Nov 19, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
450
Planned (sponsor's estimate)
Start
Dec 19, 2019
Primary completion
Feb 13, 2032
Study completion Oct 13, 2032
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- Collaborators
- Daiichi Sankyo
- First posted
- Nov 15, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) with or without chemotherapy in combination with vibostolimab (MK-7684), boserolimab (MK-5890), MK-4830, MK-0482, I-DXd, or HER3-DXd in treatment-naïve participants with advanced squamous or non-squamous NSCLC. This study is one of the pembrolizumab substudies being conducted under one pembrolizumab umbrella master protocol (MK-3475-U01/KEYMAKER-U01).
Conditions
- Carcinoma, Non-Small-Cell Lung
Interventions
PembrolizumabBiological
IV infusion
CarboplatinDrug
IV infusion
PaclitaxelDrug
IV infusion
PemetrexedDrug
IV infusion
VibostolimabBiological
IV infusion
BoserolimabBiological
IV infusion
MK-4830Biological
IV infusion
MK-0482Biological
IV Infusion
Ifinatamab Deruxtecan (I-DXd)Biological
IV infusion
HER3-DXdBiological
IV Infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Objective Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)Time frame: Up to approximately 24 months
- Part B: Number of Participants Who Experience One or More Adverse Events (AEs)Time frame: Up to approximately 27 months
- Part B: Number of Participants Who Discontinue Study Intervention Due to an Adverse Event (AE)Time frame: Up to approximately 24 months
- Part B: Number of Participants Who Experience a Dose Limiting Toxicity (DLT)Time frame: Up to approximately 3 Weeks
Locations
47 sites in 10 countries. Site status is shown where the registry gives one.
Banner MD Anderson Cancer Center ( Site 0001)
Gilbert, Arizona · Completed
City of Hope ( Site 0014)
Duarte, California · Completed
UCSF Medical Center at Mission Bay ( Site 0007)
San Francisco, California · Completed
Georgetown University ( Site 0036)
Washington D.C., District of Columbia · Completed
University of Kentucky Markey Cancer Center ( Site 0019)
Lexington, Kentucky · Completed
MedStar Franklin Square Medical Center ( Site 0033)
Baltimore, Maryland · Completed
Massachusetts General Hospital ( Site 0003)
Boston, Massachusetts · Completed
Dana Farber Cancer Institute ( Site 0002)
Boston, Massachusetts · Completed
Oncology Hematology West, PC DBA Nebraska Cancer Specialists ( Site 0031)
Omaha, Nebraska · Completed
Dartmouth Hitchcock Medical Center ( Site 0016)
Lebanon, New Hampshire · Recruiting
John Theurer Cancer Center at Hackensack University Medical Center ( Site 0037)
Hackensack, New Jersey · Completed
Laura and Isaac Perlmutter Cancer Center ( Site 0034)
New York, New York · Completed
Sanford Fargo Medical Center ( Site 0039)
Fargo, North Dakota · Recruiting
Cleveland Clinic Main ( Site 0006)
Cleveland, Ohio · Completed
The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 0015)
Columbus, Ohio · Recruiting
Abramson Cancer Center of the University of Pennsylvania ( Site 0010)
Philadelphia, Pennsylvania · Recruiting
Sanford Cancer Center ( Site 0038)
Sioux Falls, South Dakota · Recruiting
The University of Texas MD Anderson Cancer Center ( Site 0009)
Houston, Texas · Recruiting
Cross Cancer Institute ( Site 0291)
Edmonton, Alberta, Canada · Recruiting
Orszagos Koranyi Pulmonologiai Intezet ( Site 0060)
Budapest, Hungary · Completed
Petz Aladar Megyei Oktato Korhaz ( Site 0062)
Győr, Győr-Moson-Sopron, Hungary · Completed
Jász-Nagykun-Szolnok Vármegyei Hetényi Géza Kórház ( Site 0061)
Szolnok, Jász-Nagykun-Szolnok, Hungary · Completed
Soroka Medical Center ( Site 0072)
Beersheba, Israel · Completed
Rambam Health Care Campus-Oncology ( Site 0076)
Haifa, Israel · Completed
Shaare Zedek Medical Center ( Site 0075)
Jerusalem, Israel · Recruiting
Meir Medical Center ( Site 0071)
Kfar Saba, Israel · Completed
Rabin Medical Center ( Site 0074)
Petah Tikva, Israel · Completed
Chaim Sheba Medical Center ( Site 0070)
Ramat Gan, Israel · Recruiting
Sourasky Medical Center ( Site 0077)
Tel Aviv, Israel · Completed
IRCCS Ospedale San Raffaele ( Site 0171)
Milan, Italy · Completed
Policlinico Gemelli di Roma ( Site 0174)
Roma, Italy · Completed
Azienda Ospedaliera Universitaria Careggi ( Site 0173)
Florence, Firenze, Italy · Completed
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworow Pluca i Klatki Pier ( Site 0151)
Warsaw, Masovian Voivodeship, Poland · Completed
Uniwersyteckie Centrum Kliniczne-Early Clinical Trials Unit ( Site 0150)
Gdansk, Pomeranian Voivodeship, Poland · Completed
Szpital Wojewódzki im. Mikoaja Kopernika w Koszalinie-Oddzial Dzienny Chemioterapii ( Site 0152)
Koszalin, West Pomeranian Voivodeship, Poland · Active not recruiting
Severance Hospital ( Site 0080)
Seoul, South Korea · Completed
Samsung Medical Center ( Site 0082)
Seoul, South Korea · Completed
Seoul National University Bundang Hospital ( Site 0081)
Seongnam-si, Kyonggi-do, South Korea · Completed
Hospital Universitario Quiron Madrid ( Site 0091)
Madrid, Spain · Completed
ICO L Hospitalet ( Site 0090)
L'Hospitalet de Llobregat, Barcelona, Spain · Completed
Showing 40 of 47 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.